Evidence map›Paper›PMID 29653628›Full record

ArticleThe Lancet. Global health2018

Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries.

Hongmei Zeng, Wanqing Chen, Rongshou Zheng, Siwei Zhang, John S Ji, Xiaonong Zou, Changfa Xia, Kexin Sun, Zhixun Yang, He Li and 34 more

5 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in The Lancet. Global health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 977 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
977citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05976893 phase4unknown statusstarted 2023, after this paper: background citation

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Ran2023Enrolled620Registered outcomes5Posted comparisons0ConditionsASCVD, Atherosclerotic Cardiovascular Disease, Cancer, Proprotein Convertase Subtilisin/Kexin Type 9 InhibitorArmsEvolocumab, Statin
Open the trial in the graph
NCT05426213 nawithdrawnnot on this mapstarted 2022, after this paper: background citation

A Real-World Study to Evaluate the Effectiveness and Safety of Robot-Assisted Bronchoscopy in Chinese Patients With Lung Lesions

TypeinterventionalSponsorAuris Health, Inc.Ran2022 to 2024Enrolled0ConditionsLung NeoplasmsArmsRobot-assisted Bronchoscopy (Monarch Platform)
NCT05557656 unknown statusnot on this mapstarted 2023, after this paper: background citation

A Real World Study of Regogfinib in the Treatment of Advanced Hepatocellular Carcinoma

TypeobservationalSponsorZhongda HospitalRan2023 to 2023Enrolled800ConditionsHepatocellular CarcinomaArmsRegorafenib 40 MG
NCT06741020 phase1 / phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Hepatic Arterial Infusion Chemotherapy and Immunotherapy (HAICI) as Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma in BCLC A/B Stage Beyond Up to Seven Criteria: An Open-Label, Single-Arm, Pilot Study

TypeinterventionalSponsorZhejiang Cancer HospitalRan2025 to 2026Enrolled10ConditionsHepatocellular Carcinoma (HCC)ArmsAdebrelimab, Oxaliplatin, Fluorouracil,Leucovorin
NCT07614256 recruitingnot on this mapstarted 2025, after this paper: background citation

A Multicenter Study of a Deep Learning Model Based on Spatial Registration of Multimodal Imaging and Digital Pathology for Predicting Clinically Significant Prostate Cancer

Typeobservational_patient_registrySponsorGuangxi Medical UniversityRan2025 to 2030Enrolled3,000ConditionsProstate Cancer (Diagnosis), Clinically Significant Prostate CancerArmsNo Intervention: Observational Cohort
3 · Its place in the literature

Who cites it

977 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. RhTSH in aiding dynamic assessment in patients with differentiated thyroid Cancer.European journal of nuclear medicine and molecular imaging · 2025
    Trial
  3. Trial
  4. Trial
  5. Trial
  6. Burden of Gastric Cancer in China from 1990 to 2023.Public health in practice (Oxford, England) · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

917 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

44 authors.

Hongmei ZengNational Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wanqing ChenNational Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: chenwq@cicams.ac.cn.
Rongshou ZhengNational Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Siwei ZhangNational Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
John S JiEnvironmental Research Center, Duke Kunshan University, Jiangsu, China; Nicholas School of the Environment, Duke University, Durham, NC, USA.
Xiaonong ZouNational Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Changfa XiaNational Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Kexin SunNational Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhixun YangNational Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
He LiNational Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ning WangKey Laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing, Beijing Office for Cancer Prevention and Control, Peking University Cancer Hospital & Institute, Beijing, China.
Renqiang HanJiangsu Center for Disease Control and Prevention, Jiangsu, China.
Shuzheng LiuHenan Cancer Hospital, Henan, China.
Huizhang LiZhejiang Provincial Office for Cancer Prevention and Control, Zhejiang Cancer Center/Cancer Hospital, Zhejiang, China.
Huijuan MuLiaoning Center for Disease Control and Prevention, Shenyang, China.
Yutong HeFourth Hospital of Hebei Medical University, Hebei, China.
Yanjun XuGuangdong Center for Disease Control and Prevention, Guangdong, China.
Zhentao FuShandong Center for Disease Control and Prevention, Shandong, China.
Yan ZhouFujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fujian, China.
Jie JiangDalian Cancer Registry, Dalian Center for Disease Control and Prevention, Liaoning, China.
Yanlei YangHaimen Cancer Registry, Haimen Center for Disease Control and Prevention, Jiangsu, China.
Jianguo ChenQidong Cancer Registry, Qidong Liver Cancer Institute, Jiangsu, China.
Kuangrong WeiZhongshan Cancer Registry, Zhongshan People's Hospital, Guangdong, China.
Dongmei FanTaixing Cancer Registry, Taixing Center for Disease Control and Prevention, Jiangsu, China.
Jian WangJianhu Cancer Registry, Jianhu Center for Disease Control and Prevention, Jiangsu, China.
Fangxian FuLinzhou Cancer Registry, Linzhou Cancer Hospital, Henan, China.
Deli ZhaoFeicheng Cancer Registry, Feicheng People's Hospital, Shandong, China.
Guohui SongCixian Cancer Registry, Cixian Institute for Cancer Prevention and Control, Hebei, China.
Jianshun ChenChangle Cancer Registry, Changle Institute for Cancer Prevention and Control, Fujian, China.
Chunxiao JiangHaining Cancer Registry, Haining Institute for Cancer Prevention and Control, Zhejiang, China.
Xin ZhouJintan Cancer Registry, Jintan Center for Disease Control and Prevention, Jiangsu, China.
Xiaoping GuDafeng Cancer Registry, Dafeng Center for Disease Control and Prevention, Jiangsu, China.
Feng JinGanyu Cancer Registry, Ganyu Center for Disease Control and Prevention, Jiangsu, China.
Qilong LiJiashan Cancer Registry, Jiashan Institute for Cancer Prevention and Control, Zhejiang, China.
Yanhua LiSihui Cancer Registry, Tumor Research Institute of Sihui City, Guangdong, China.
Tonghao WuDonghai Cancer Registry, Donghai Center for Disease Control and Prevention, Jiangsu, China.
Chunhua YanGuanyun Cancer Registry, Guanyun Center for Disease Control and Prevention, Jiangsu, China.
Jianmei DongLianyungang Cancer Registry, Lianyungang Center for Disease Control and Prevention, Jiangsu, China.
Zhaolai HuaYangzhong Cancer Registry, Yangzhong Institute for Cancer Prevention and Control, Jiangsu, China.
Peter BaadeCancer Research Centre, Cancer Council Queensland, Brisbane, QLD, Australia.
Freddie BrayCancer Surveillance Section, International Agency for Research on Cancer, Lyon France.
Ahmedin JemalSurveillance and Health Services Research Program, American Cancer Society, Atlanta, GA, USA.
Xue Qin YuCancer Research Division, Cancer Council New South Wales, Sydney, NSW, Australia.
Jie HeNational Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: hejie@cicams.ac.cn.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundFrom 2003 to 2005, standardised 5-year cancer survival in China was much lower than in developed countries and varied substantially by geographical area. Monitoring population-level cancer survival is crucial to the understanding of the overall effectiveness of cancer care. We therefore aimed to investigate survival statistics for people with cancer in China between 2003 and 2015.

methodsWe used population-based data from 17 cancer registries in China. Data for the study population was submitted by the end of July 31, 2016, with follow-up data on vital status obtained on Dec 31, 2015. We used anonymised, individual cancer registration records of patients (aged 0-99 years) diagnosed with primary, invasive cancers from 2003 to 2013. Patients eligible for inclusion had data for demographic characteristics, date of diagnosis, anatomical site, morphology, behaviour code, vital status, and last date of contact. We analysed 5-year relative survival by sex, age, and geographical area, for all cancers combined and 26 different cancer types, between 2003 and 2015. We stratified survival estimates by calendar period (2003-05, 2006-08, 2009-11, and 2012-15).

findingsThere were 678 842 records of patients with invasive cancer who were diagnosed between 2003 and 2013. Of these records, 659 732 (97·2%) were eligible for inclusion in the final analyses. From 2003-05 to 2012-15, age-standardised 5-year relative survival increased substantially for all cancers combined, for both male and female patients, from 30·9% (95% CI 30·6-31·2) to 40·5% (40·3-40·7). Age-standardised 5-year relative survival also increased for most cancer types, including cancers of the uterus (average change per calendar period 5·5% [95% CI 2·5-8·5]), thyroid (5·4% [3·2-7·6]), cervix (4·5% [2·9-6·2]), and bone (3·2% [2·1-4·4]). In 2012-15, age-standardised 5-year survival for all patients with cancer was higher in urban areas (46·7%, 95% CI 46·5-47·0) than in rural areas (33·6%, 33·3-33·9), except for patients with oesophageal or cervical cancer; but improvements in survival were greater for patients residing in rural areas than in urban areas. Relative survival decreased with increasing age. The increasing trends in survival were consistent with the upward trends of medical expenditure of the country during the period studied.

interpretationThere was a marked overall increase in cancer survival from 2003 to 2015 in the population covered by these cancer registries in China, possibly reflecting advances in the quality of cancer care in these areas. The survival gap between urban and rural areas narrowed over time, although geographical differences in cancer survival remained. Insight into these trends will help prioritise areas that need increased cancer care.

fundingNational Key R&D Program of China, PUMC Youth Fund and the Fundamental Research Funds for the Central Universities, and Major State Basic Innovation Program of the Chinese Academy of Medical Sciences.

Indexed as

AdolescentAdultAgedAged, 80 and overCancer SurvivorsChildChild, PreschoolChinaFemaleHumansInfantInfant, NewbornMaleMiddle AgedNeoplasmsRegistries

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.